Sitemap - 2021 - COVID-19 Science Updates
5 Scandinavian countries limit or halt Moderna
Effectiveness Moderna vaccine vs. Delta, Mu, and other emerging variants
Molnupiravir, an oral antiviral treatment for COVID-19
Efficient border testing via reinforcement learning
UK Committee opts not to recommend vaccination of 12-15 year olds
Immunity from natural infection vs vaccination: systematic review
Reinfection by Gamma variant in Manaus, Brazil
Vaccine effectiveness in the US: Moderna 93%, Pfizer 88%, J&J 71%
J&J says 2 doses 100% effective against severe Covid
Vaccines in children and adolescents: a systematic review
Why vaccinate people who have had Covid?
Booster shots: what is the evidence?
Cases, hospitalizations and deaths by vaccination status in 13 US jurisdictions
Effectiveness of governmental strategies for managing COVID-19
New WHO Variant of Interest (Mu): what we know
Effectiveness of vaccination: systematic review and meta-analysis
Vaccines: 53-84% vs Delta infection, 85-96% vs hospitalization
Delta doubles risk of hospital admission (2.26x)
mRNA vaccines 66% effective against Delta
A grim warning from Israel: Delta
Inactivated vaccine 59% effective vs Delta infection, 70% vs moderate Covid
School closures and safe reopening
Fully vaccinated: 20% cases, 15% hospitalizations in New York
50+ long-term effects of COVID-19: a systematic review and meta-analysis
Viruses, vaccines and variants versus efficacy, effectiveness and escape
Reinfection: 0.2% with previous Covid, 1.8% with vaccines
University of Illinois program: zero hospitalizations or deaths in Fall 2020
Chinese strategy in controlling reemergent local outbreaks
"Around 50% to 60% reduced risk" of infection when fully vaccinated
Leaked CDC document: vaccinated people spreading Delta variant
New Lambda variant might be resistant to vaccines
Screening before music concerts and mass sport events
Effectiveness of vaccines against Delta variant
Pfizer vaccine seems 94% effective against South African variant
Effectiveness of vaccines against infection: living systematic review
WHO pressures China on pandemic origin
Chinese vaccine 65.9% effective in Chile (n=10,200,000)
Myocarditis in 30 patients after mRNA vaccines
Critical exposure time in a small indoor space is less than 1 h
One vaccine against multiple coronaviruses
Breakthrough infections reported to CDC, Jan-Apr 2021
EU adds another rare side effect to AstraZeneca shot
Mixed Oxford/Pfizer vaccine schedules generate robust immune response
New data on contact tracing effectiveness
Emergence and spread of new variant in Mexico
Less effective vaccines still protect against severe disease
Risk of hospital admission doubled with Delta variant
90% of new cases in the UK are Delta (Indian) variant
Prior infection protects against reinfection, even in the absence of antibodies
Impact of vaccination on new infections
Effective mitigation: a systematic review
Long-term side effects of vaccines?
39% of non-hospitalized Covid patients did not neutralize B.1.351
Reinfection with variants (breakthrough infections)
Indian variant escapes antibodies partially
Cases surge in Chile despite high vaccination and lockdown
New Dog Coronavirus Isolated from Pneumonia Patient in Malaysia
0.0055% serious side effects following 17.7 million doses in Canada
Delaying the second dose to 12 weeks may 3.5x antibody response in people aged 80+
Cases surge in most vaccinated nation on Earth (Seychelles)
Ireland: 0.1% of cases linked to outdoor transmission
Impact of COVID-19 vaccines on mortality in England
Effectiveness of vaccines against variants
Recovered individuals who continued to test positive were not infectious to others
Vaccination after infection enhances antibody responses against variants
627,383 vaccinated in the UK: side-effects & infections
No local cases for 253 days in Taiwan without strict lockdown or school closure—how?
Safety and efficacy of single-dose J&J vaccine in 19,630 participants
Lockdown did not appear to be linked with death rate
Antibodies remained high 6 months after the second Moderna dose
Vaccine side-effect or coincidence?
4/16—Johnson & Johnson vaccine and blood clots
4/14—Outdoor Transmission: A Systematic Review
4/12—South African variant may evade protection from Pfizer vaccine
4/9—B.1.1.7: Reduced neutralization, but "widespread escape" from antibodies not observed
4/7—AstraZeneca vaccine and blood clots
4/5—Increase in SARS-CoV-2 after vaccination in health care workers in California
4/2—Pfizer says vaccine 100% effective against South African variant
3/31—14 countries and WHO accuse China of withholding data
3/29—Default appointments and onsite vaccination increase uptake
3/26—UK variant 61-64% more deadly
3/24—Vaccine response in pregnant and lactating women: a cohort study
3/22—How long does infection protect from reinfection? [Rapid review]
3/19—Understanding policy variation in pandemic response
3/17—A 30-item checklist for evaluating crisis communication
3/15—15%–24% lower odds of severe COVID-19 with influenza vaccination
3/12—EU countries halt AstraZeneca vaccine over blood clots
3/10—Vaccinating previously infected individuals
3/8—UK variant higher R (43–90%), hospitalisations (64%), and mortality (61%)
3/5—WHO "to scrap interim report" on origins of COVID-19
3/3—Pfizer vaccine prevents asymptomatic infections
3/1—Lockdowns "at least" 5–10x more harmful than COVID-19
2/26—UK variant surge: reassessing vaccine deployment?
2/24—Age groups that sustain resurging COVID-19 epidemics
2/22—CDC: Fully vaccinated people do not need to quarantine after covid-19 exposure
2/19—Delayed vaccine second dose: Pfizer 92.6% effective; Moderna 92.1%
2/15—New US variant, UK mutation, and studies of allergic reactions after vaccine
2/12—CDC Task Force: Building Confidence in COVID-19 Vaccines
2/10—Oxford vaccine 10% effective in South Africa; Pfizer 81% to 146% in lab tests
2/8—No herd immunity despite 76% of population infected; variants?
2/5—French study predicts vaccine acceptance 27·4% to 61·3%
2/3—Russian vaccine 91·6% efficacy; Oxford 76% 22-90 days after 1 dose
2/1—SARS-CoV-2 evolution and vaccines: cause for concern?
1/29—Novavax says vaccine 89% efficacy in UK, 60% in South Africa
1/27—"Realistic possibility" that UK variant ~30% more deadly
1/25—Moderna vaccine less effective against South African variant
01/22—Fast-spreading COVID variant can elude immune responses
1/20—Efficacy, Safety, and Durability of the Moderna & Pfizer Vaccines